"Il Pascale è il maggiore IRCCS Oncologico del Mezzogiorno ed è Centro di Riferimento per la rete oncologica nazionale e regionale. L'Istituto persegue finalità di ricerca prevalentemente clinica, e di ricerca applicata nel campo biomedico e in quello dell'organizzazione e gestione dei servizi sanitari, dedicando grande impegno alle problematiche più ampie del paziente oncologico, che vanno dall'assistenza psicologica ai problemi nutrizionali, alla terapia del dolore, alle cure palliative in genere, fino alle fasi più delicate della malattia."

During the past decade, National Cancer Institute - IRCCS "Fondazione G. Pascale" conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 1 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Cancer Institute - IRCCS "Fondazione G. Pascale"" #1 sponsor was "Clovis Oncology, Inc." with 1 trials, followed by "ISA Pharmaceuticals" with 1 trials sponsored, "Mersana Therapeutics" with 1 trials sponsored, "Puma Biotechnology, Inc." with 1 trials sponsored and "Rain Oncology Inc" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Cancer Institute - IRCCS "Fondazione G. Pascale"" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator and "Regeneron Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "National Cancer Institute - IRCCS "Fondazione G. Pascale"" are "Advanced Solid Tumor" (1 trials), "Dedifferentiated Liposarcoma" (1 trials), "Gynecologic Cancer" (1 trials), "HER2+ Metastatic Breast Cancer (MBC)" (1 trials) and "HPV16 Positive" (1 trials). Many other conditions were trialed in "National Cancer Institute - IRCCS "Fondazione G. Pascale"" in a lesser frequency.

Most popular intervention types in "National Cancer Institute - IRCCS "Fondazione G. Pascale"" are "Drug" (5 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cemiplimab" (1 trials), "ISA101b" (1 trials), "Lucitanib" (1 trials), "Nivolumab" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "National Cancer Institute - IRCCS "Fondazione G. Pascale"" are 5 trials for "All" genders.

Currently, there are NaN active trials in "National Cancer Institute - IRCCS "Fondazione G. Pascale"". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in National Cancer Institute - IRCCS "Fondazione G. Pascale", 1 suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in National Cancer Institute - IRCCS "Fondazione G. Pascale", 2 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".